impact on quality of life (5/10); left lymph node pain; gum redness; left lymph node enlargement; tender sinus; dysentery; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the ra-web. regulatory number: it-minisal02-843013. a 54 year-old female patient received bnt162b2 (comirnaty), intramuscular, administered in arm left, administration date 30jan2022 12:12 (lot number: fn6618) as dose 1, 0.3 ml single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. the following information was reported: lymph node pain (disability) with onset 31jan2022, outcome "recovering", described as "left lymph node pain"; gingival erythema (disability) with onset 31jan2022, outcome "recovering", described as "gum redness"; lymphadenopathy (disability) with onset 31jan2022, outcome "recovering", described as "left lymph node enlargement"; sinus pain (disability) with onset 31jan2022, outcome "recovering", described as "tender sinus"; dysentery (disability) with onset 31jan2022, outcome "recovering", described as "dysentery"; quality of life decreased (disability), outcome "recovering", described as "impact on quality of life (5/10)". the patient underwent the following laboratory tests and procedures: quality of life decreased: impact on quality of life (5/10). therapeutic measures were taken as a result of lymph node pain, gingival erythema, lymphadenopathy, sinus pain, dysentery, quality of life decreased. reporter comment: no disease. no follow-up attempts are possible. no further information is expected